Modest Alcohol Consumption Lowers Risk and Severity of Liver Disease

20 Apr 2012 --- Schwimmer and colleagues discovered that the benefits of modest alcohol consumption were compelling, at least in terms of reducing the odds of patients with NAFLD from developing more severe forms of the disease.

20 April 2012 --- People with nonalcoholic fatty liver disease (NALFD) who consume alcohol in modest amounts – no more than one or two servings per day – are half as likely to develop hepatitis as non-drinkers with the same condition, reports a national team of scientists led by researchers at the University of California, San Diego School of Medicine.

The findings are published in the April 19, 2012 online issue of The Journal of Hepatology.

NALFD is the most common liver disease in the United States, affecting up to one third of American adults. It's characterized by abnormal fat accumulation in the liver. The specific cause or causes is not known, though obesity and diabetes are risk factors. Most patients with NAFLD have few or no symptoms, but in its most progressive form, known as nonalcoholic steatohepatitis or NASH, there is a significantly heightened risk of cirrhosis, liver cancer and liver-related death.

NALFD is also a known risk factor for cardiovascular disease (CVD). Patients with NAFLD are approximately two times more likely to die from coronary heart disease than from liver disease. The study's authors wanted to know if the well-documented heart-healthy benefits of modest alcohol consumption outweighed alcohol's negative effects.

"We know a 50-year-old patient with NAFLD has a higher risk of CVD," said Jeffrey Schwimmer, MD, associate professor of clinical pediatrics at UC San Diego, director of the Fatty Liver Clinic at Rady Children's Hospital-San Diego and senior author. "Data would suggest modest alcohol consumption would be beneficial (in reducing the patient's CVD risk) if you don't take liver disease into account. When you do take liver disease into account, however, the usual medical recommendation is no alcohol whatsoever."

Schwimmer and colleagues discovered that the benefits of modest alcohol consumption were compelling, at least in terms of reducing the odds of patients with NAFLD from developing more severe forms of the disease. Patients with NASH are 10 times more likely to progress to cirrhosis, the final phase of chronic liver disease. Cirrhosis is the 12th leading cause of death in the U.S., killing an estimated 27,000 Americans annually.

"Our study showed that those people with modest alcohol intake – two drinks or less daily – had half the odds of developing NASH than people who drank no alcohol," said Schwimmer. "The reasons aren't entirely clear. It's known that alcohol can have beneficial effects on lipid levels, that it increases 'good' cholesterol, which tends to be low in NAFLD patients. Alcohol may improve insulin sensitivity, which has a role in NAFLD. And depending upon the type of alcohol, it may have anti-inflammatory effects."

The study also found that in patients with NAFLD, modest drinkers experienced less severe liver scarring than did lifelong non-drinkers.

The study did not evaluate the effects of different types of alcohol, such as beer or spirits. Schwimmer said to do so would require a much larger study. Also, the study's findings do not apply to children. All of the participants in the study were age 21 and older.

The current paper is based on analyses of 600 liver biopsies of patient's with NAFLD by a national panel of pathologists who had no identifying clinical information about the samples. The study excluded anyone who averaged more than two alcoholic drinks per day or who reported consuming five or more drinks in a day (binge-drinking) at least once a month. All of the patients were at least 21 years of age.

Schwimmer said the findings indicate patients with liver disease should be treated individually, with nuance.

"For a patient with cirrhosis or viral hepatitis, the data says even small amounts of alcohol can be bad. But that may not be applicable to all forms of liver disease. Forty million Americans have NAFLD. Physicians need to look at their patient's overall health, their CVD risk, their liver status, whether they're already drinking modestly or not. They need to put all of these things into a framework to determine risk. I suspect modest alcohol consumption will be an appropriate recommendation for many patients, but clearly not all."

Related Articles

Nutrition & Health News

BASF targets fatty liver disease with US launch of Hepaxa product

23 Feb 2018 --- BASF is launching Hepaxa to help patients manage non-alcoholic fatty liver disease in what the corporation describes as “the first dedicated product in the US” to potentially assist tens of millions of patients with one of the most common forms of chronic liver disease. And it could begin to “turn around” non-alcoholic fatty liver disease (NAFLD) in as little as six months, according to BASF executives. 

Nutrition & Health News

Chronic heavy drinking major risk factor for dementia: The Lancet

21 Feb 2018 --- Excessive alcohol use is a major risk factor for onset of all types of dementia, especially early-onset dementia, according to a French nationwide observational study, published in The Lancet Public Health journal. Previous research has shown mixed results regarding the effect of alcohol on cognitive health, with some studies showing a possible benefit of light to moderate drinking, while others have found detrimental effects of heavy drinking on dementia risk.

Nutrition & Health News

Low-carb diet found to help battle fatty liver disease

20 Feb 2018 --- A carbohydrate-restricted diet can lead to “rapid and dramatic” reductions of liver fat and other cardiometabolic risk factors, along with marked decreases in the synthesis of hepatic fat, reveals a study published last week in Cell Metabolism. The study results could lead to improved treatments for non-alcoholic fatty liver disease (NAFLD). 

Nutrition & Health News

Façade? British Nutrition Foundation questions benefit of skin beauty nutraceuticals

14 Feb 2018 --- Although there is a growing market for orally consumed beauty supplements that promise “youthful,” “firm” and “glowing” skin, the evidence to support some of the ingredients used in these popular, and often costly, products is limited. This is according to a review of published research conducted by the British Nutrition Foundation (BNF). The review concludes that nutraceuticals for skin may not add further benefit to the effects already obtained from a healthy diet. 

Nutrition & Health News

What happens in the gut after too much fructose? Mouse study sheds light on role of small intestine

07 Feb 2018 --- In mice, fructose is processed mainly in the small intestine, not in the liver as had previously been suspected, Princeton University researchers report. However, sugary drinks and processed high-sugar foods may overwhelm the small intestine and spill into the liver for processing. Additionally, the authors note that the ability of the small intestine to process fructose is higher after a meal. Although the study was conducted in mice, the researchers recommend "the most old-fashioned advice in the world" for humans: Limit sweets to moderate quantities after meals, and do not have sweet drinks away from meal time.

More Articles
URL : http://www.nutritioninsight.com:80/news/Modest-Alcohol-Consumption-Lowers-Risk-and-Severity-of-Liver-Disease.html